Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen

NCT05506943 is registered in ClinicalTrials.gov with Compass Therapeutics as lead sponsor.

NCT NCT05506943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05506943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Lead sponsor
Compass Therapeutics
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 9, 2023
Completion date
August 31, 2027
Enrollment
168 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

ampullary cancer, biliary tract cancer, cholangiocarcinoma, gall bladder cancer